Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Metabolic Drug Survey Highlights Cancer Cell Dependencies and Vulnerabilities

Tea Pemovska, PhD, Johannes Bigenzahn, MD PhD, Ismet Srndic, MSc, Alexander Lercher, MSc, Andreas Bergthaler, PhD, Adrian Cesar Razquin, PhD, Felix Kartnig, MD, Philipp B. Staber, MD PhD, Giulio Superti Furga, PhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-134769

Published: 2020

Journal Articles

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Christoph Kornauth, Tea Pemovska, PhDMSc,BSc, Gregory Ian Vladimer, PhD, Günther Bayer, Michael Bergmann, Sandra Eder, Ruth Eichner, Harald Esterbauer, MD PhD, Ruth Exner, Verena Felsleitner-Hauer, Maurizio Forte, MSc, Alexander Gaiger, Hildegard T. Greinix, MD, Wolfgang Gstöttner, Marcus Hacker, Alexander Hauswirth, MD, Tim Heinemann, Daniel Heintel, Mir Ali Reza Hoda, Ulrich Jaeger, Lukas Kazianka, MD, Lukas Kenner, MD, Barbara Kiesewetter, MD, Nikolaus Krall, PhD, Trang Le, BSc, Simone Lubowitzki, Marius E Mayerhoefer, Elisabeth Menschel, Olaf Merkel, PhD, Katsuhiro Miura, MD PhD, Leonhard Muellauer, MD PhD, Peter Neumeister, MD, Thomas Noesslinger, MD, Katharina Ocko, Leopold Öhler, Michael Panny, MD, Alexander Pichler, MD, Edit Anna Porpaczy, MD, Gerald Prager, MD, Markus Raderer, Robin Ristl, Reinhard Ruckser, MD, Julius Salamon, Ana-Iris Schiefer, Ann-Sofie Schmolke, MD, Ilse Schwarzinger, MD, Edgar Selzer, Cathrin Skrabs, Wolfgang R. Sperr, MD, Ismet Srndic, MSc, Renate Thalhammer, MD, Peter Valent, MD, Emiel van der Kouwe, PharmD, Katrina Vanura, PhD, Stefan Vogt, Cora Waldstein, Dominik Wolf, Univ. Prof. Dr., Christoph Zielinski, Ingrid Simonitsch-Klupp, MD, Giulio Superti-Furga, PhD, Berend Snijder, PhD, Philipp B. Staber, MD PhD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140831

Published: 2020

Journal Articles

SLC20A1 at the Interface between Macrophages and Red Blood Cells

Federica Quattrone, MSc, Riem Gawish, PhD, Rui Martins, PhD, Anna-Dorothea Gorki, PhD, Martin Watzenboeck, MD, Anastasiya Hladik, Karin Lakovits, Manuele Rebsamen, PhD, Enrico Girardi, PhD, Giulio Superti-Furga, PhD, Sylvia Knapp, MD PhD

Blood (2019) 134 (Supplement_1): 428.

https://doi.org/10.1182/blood-2019-123758

Published: 2019

Journal Articles

Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML

Tea Pemovska, PhD, Gregory Ian Vladimer, PhD, Vitaly Sedlyarov, PhD, Emir Hadzijusufovic, DVM, Karoline Veronika Gleixner, MD, Alexandra Keller, MSc, Berend Snijder, PhD, Nikolaus Krall, PhD, Oscar Lopez de la Fuente, BSc, Mathias A Schneeweiss, MD, Wolfgang R. Sperr, MD, Paul Knöbl, MD PhD, Klaus Geissler, MD, Philipp Bernhard Staber, MD PhD, Ulrich Jaeger, MD, Peter Valent, MD, Giulio Superti Furga, PhD

Blood (2017) 130 (Supplement 1): 4227.

https://doi.org/10.1182/blood.V130.Suppl_1.4227.4227

Published: 2017

Journal Articles

Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies

Blood (2017) 130 (Supplement 1): 855.

https://doi.org/10.1182/blood.V130.Suppl_1.855.855

Published: 2017

Journal Articles

Unbiased Profiling of the Immunomodulatory Properties of Soluble Proteins

Nikolaus Krall, PhD, Gregory Ian Vladimer, PhD, Berend Snijder, PhD, Noemi Meszaros, Nicole Müller-Sienerth, PhD, Gavin Wright, Giulio Superti-Furga, PhD

Blood (2017) 130 (Supplement 1): 2293.

https://doi.org/10.1182/blood.V130.Suppl_1.2293.2293

Published: 2017

Journal Articles

Integrated ATAC-Seq and Chemosensitivity Profiling Identifies Rational Drug Combinations in Ibrutinib-Treated CLL Patients

Blood (2017) 130 (Supplement 1): 800.

https://doi.org/10.1182/blood.V130.Suppl_1.800.800

Published: 2017

Journal Articles

Germline RBBP6 mutations in familial myeloproliferative neoplasms

Blood (2016) 127 (3): 362–365.

https://doi.org/10.1182/blood-2015-09-668673

Published: 2016

Includes: Supplemental data

Journal Articles

Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML

Blood (2014) 124 (21): 1800.

https://doi.org/10.1182/blood.V124.21.1800.1800

Published: 2014

Journal Articles

Frequent Mutations in the Calreticulin Gene CALR in Myeloproliferative Neoplasms

Blood (2013) 122 (21): LBA-1.

https://doi.org/10.1182/blood.V122.21.LBA-1.LBA-1

Published: 2013

Journal Articles

Deficiency Of JAGN1 Causes Severe Congenital Neutropenia Associated With Defective Secretory Pathway and Aberrant Myeloid Cell Homeostasis

Blood (2013) 122 (21): 439.

https://doi.org/10.1182/blood.V122.21.439.439

Published: 2013

Journal Articles

Germline RBBP6 Mutations In Myeloproliferative Neoplasms

Blood (2013) 122 (21): 267.

https://doi.org/10.1182/blood.V122.21.267.267

Published: 2013

Journal Articles

Nilotinib Exerts Direct Pro-Atherogenic and Anti-Angiogenic Effects On Vascular Endothelial Cells: A Potential Explanation For Drug-Induced Vasculopathy In CML

Hadzijusufovic Emir, DVM, Karin Albrecht-Schgoer, PhD, Kilian Huber, PhD, Florian Grebien, PhD, Gregor Eisenwort, MD, PhD, Wilfried Schgoer, MD, PhD, Christoph Kaun, Susanne Herndlhofer, Markus Theurl, PhD, Sabine Cerny-Reiterer, D.V.M., Gregor Hoermann, M.D., Ph.D., Wolfgang R Sperr, M.D., Rix Uwe, PhD, Johann Wojta, PhD, Dominik Wolf, MD, Giulio Superti-Furga, PhD, Rudolf Kirchmair, MD, Peter Valent

Blood (2013) 122 (21): 257.

https://doi.org/10.1182/blood.V122.21.257.257

Published: 2013

Journal Articles

KIT-D816V–independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib

Karoline V. Gleixner, Matthias Mayerhofer, Sabine Cerny-Reiterer, Gregor Hörmann, Uwe Rix, Keiryn L. Bennett, Emir Hadzijusufovic, Renata A. Meyer, Winfried F. Pickl, Jason Gotlib, Hans-Peter Horny, Andreas Reiter, Gerlinde Mitterbauer-Hohendanner, Giulio Superti-Furga, Peter Valent

Blood (2011) 118 (7): 1885–1898.

https://doi.org/10.1182/blood-2010-06-289959

Published: 2011

Includes: Supplemental data

Journal Articles

Bcr-Abl Directly Activates Stat5 Independent of Jak2

Oliver D. Hantschel, MSc, PhD, Eva Eckelhart, MSc, Ines Kaupe, MSc, Florian Grebien, MSc, PhD, Kay-Uwe Wagner, PhD, Veronika Sexl, MD, Giulio Superti-Furga, PhD

Blood (2010) 116 (21): 511.

https://doi.org/10.1182/blood.V116.21.511.511

Published: 2010

Journal Articles

Functional Genomic and Proteomic Characterization of Normal and Oncogenic CEBPA Variants In Myeloid Cells

Florian Grebien, Roberto Giambruno, Keiryn L Bennett, Jacques Colinge, Giulio Superti-Furga

Blood (2010) 116 (21): 3873.

https://doi.org/10.1182/blood.V116.21.3873.3873

Published: 2010

Journal Articles

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

Daniel W. Sherbenou, Oliver Hantschel, Ines Kaupe, Stephanie Willis, Thomas Bumm, Lalita P. Turaga, Thoralf Lange, Kim-Hien Dao, Richard D. Press, Brian J. Druker, Giulio Superti-Furga, Michael W. Deininger

Blood (2010) 116 (17): 3278–3285.

https://doi.org/10.1182/blood-2008-10-183665

Published: 2010

Includes: Supplemental data

Journal Articles

The Bcr-Abl SH2-Kinase Domain Interface Is Critical for Leukemogenesis and An Additional Therapeutic Target in CML.

Oliver D. Hantschel, PhD, Florian Grebien, Ines Kaupe, Boris Kovacic, John Wojcik, Gerald D Gish, Shohei Koide, Hartmut Beug, Tony Pawson, Giulio Superti-Furga

Blood (2009) 114 (22): 37.

https://doi.org/10.1182/blood.V114.22.37.37

Published: 2009

Journal Articles

Effects of Bosutinib (SKI-606) in CML: Kinase Target Profile, Effects on BCR/ABL Mutants, and Synergism with Dasatinib in T315I+ Cells

Karoline Veronika Gleixner, MD, Lily L Remsing Rix, Christian Baumgartner, Uwe Rix, Alexander Gruze, Renata Anna Meyer, M.D., Winfried F. Pickl, MD, Christian Sillaber, Martin Augustin, Jeff Till, Giulio Superti-Furga, Peter Valent, MD

Blood (2008) 112 (11): 3195.

https://doi.org/10.1182/blood.V112.11.3195.3195

Published: 2008

Journal Articles

Structural Positioning of the SH2 Domain Is Critical for Bcr-Abl Kinase Activity, Signal Transduction and Oncogenic Transformation

Oliver D. Hantschel, PhD, Florian Grebien, Ines Kaupe, Giulio Superti-Furga

Blood (2008) 112 (11): 569.

https://doi.org/10.1182/blood.V112.11.569.569

Published: 2008

NARROW

Metabolic Drug Survey Highlights Cancer Cell Dependencies and Vulnerabilities

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

SLC20A1 at the Interface between Macrophages and Red Blood Cells

Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML

Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies

Unbiased Profiling of the Immunomodulatory Properties of Soluble Proteins

Integrated ATAC-Seq and Chemosensitivity Profiling Identifies Rational Drug Combinations in Ibrutinib-Treated CLL Patients

Germline RBBP6 mutations in familial myeloproliferative neoplasms

Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML

Frequent Mutations in the Calreticulin Gene CALR in Myeloproliferative Neoplasms

Deficiency Of JAGN1 Causes Severe Congenital Neutropenia Associated With Defective Secretory Pathway and Aberrant Myeloid Cell Homeostasis

Germline RBBP6 Mutations In Myeloproliferative Neoplasms

Nilotinib Exerts Direct Pro-Atherogenic and Anti-Angiogenic Effects On Vascular Endothelial Cells: A Potential Explanation For Drug-Induced Vasculopathy In CML

KIT-D816V–independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib

Bcr-Abl Directly Activates Stat5 Independent of Jak2

Functional Genomic and Proteomic Characterization of Normal and Oncogenic CEBPA Variants In Myeloid Cells

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

The Bcr-Abl SH2-Kinase Domain Interface Is Critical for Leukemogenesis and An Additional Therapeutic Target in CML.

Effects of Bosutinib (SKI-606) in CML: Kinase Target Profile, Effects on BCR/ABL Mutants, and Synergism with Dasatinib in T315I+ Cells

Structural Positioning of the SH2 Domain Is Critical for Bcr-Abl Kinase Activity, Signal Transduction and Oncogenic Transformation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only